Welcome to our dedicated page for CYTOKINETICS SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics reported that the European Commission has approved MYQORZO® (aficamten) tablets at 5 mg, 10 mg, 15 mg and 20 mg strengths. The drug is indicated for adult patients with symptomatic, obstructive hypertrophic cardiomyopathy classified as New York Heart Association class II–III. This approval allows Cytokinetics to offer a novel allosteric, reversible inhibitor of cardiac myosin motor activity as a treatment option for this specific heart condition across the European Union.
Cytokinetics executive Andrew Callos reported an option exercise and share sale. On 02/05/2026, the EVP and Chief Commercial Officer exercised 15,000 non-qualified stock options at $23.26 per share and received 15,000 shares of common stock.
That same day, he sold 15,000 shares of common stock at $61.93 per share, leaving him with 50,440 shares of common stock held directly and 84,000 stock options remaining. The reported options were originally granted on 03/31/2022 and are scheduled to vest over four years, with an expiration date of 03/31/2031.
Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an option exercise and matching share sale in company common stock. On February 2, 2026, he exercised 886 shares under an incentive stock option at $37.63 per share.
The same day, he sold 886 common shares at $62.10 per share. After these transactions, Callos directly held 50,440 common shares and 886 incentive stock options. The option grant vests in equal monthly installments over four years from the grant date.
Cytokinetics director James M. Daly reported receiving company stock as board compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to members of the board of directors. Following this transaction, Daly beneficially owned 197 shares of Cytokinetics common stock in direct ownership.
Cytokinetics director Nancy Wysenski reported receiving additional company stock as part of her board compensation. On 01/15/2026, she acquired 98 shares of common stock at a reported price of $63.44 per share, taken in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, she beneficially owned 30,971 shares of Cytokinetics common stock, held directly.
Cytokinetics director Wendell Wierenga reported a routine equity compensation transaction. On January 15, 2026, he acquired 98 shares of Cytokinetics common stock at $63.44 per share. According to the footnote, these fully vested shares were received in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this grant, he beneficially owns 32,542 common shares directly.
Cytokinetics director Edward M. Kaye, M.D. reported receiving additional company stock as part of his board compensation. On 01/15/2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. According to the filing, these were fully vested shares issued in lieu of a cash retainer under an equity-in-lieu-of-cash option available to board members. After this transaction, Dr. Kaye directly owned 10,174 shares of Cytokinetics common stock.
Cytokinetics director John T. Henderson reported receiving 334 shares of Cytokinetics common stock on 01/15/2026 at a value of $63.44 per share. These fully vested shares were issued in lieu of a cash retainer under the company’s Equity in Lieu of Cash Retainer Option available to members of the Board of Directors.
After this award, Henderson beneficially owned 74,912 shares of Cytokinetics common stock directly, and an additional 83 shares indirectly through his spouse. This filing reflects routine equity compensation for board service rather than an open-market share purchase.
Cytokinetics director Robert Arthur Harrington reported receiving additional company stock as compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These were fully vested shares received in lieu of a cash retainer under an equity compensation option available to members of the Board of Directors.
Following this transaction, Harrington beneficially owned 18,739 shares of Cytokinetics common stock in direct ownership. The filing reflects routine director compensation paid in stock rather than cash, with no sales reported.
Cytokinetics executive Dr. Malik, EVP of Research & Development, reported insider transactions dated 12/16/2025. The disclosure shows an exercise of 2,200 incentive stock options at $10.60 per share, creating 2,200 shares of common stock, followed by a same-day sale of 2,200 common shares at $61.24 per share. After these transactions, Dr. Malik directly beneficially owns 138,552 shares of Cytokinetics common stock.